SCHEMBL3939233

SCHEMBL3939233

CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(OC(F)(F)F)cc3)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 16/20 1.00
HRH3 Q9Y5N1 2/20 0.63
P2RY1 P47900 1/20 0.53
FAAH O00519 1/20 0.53
HPGD P15428 1/20 0.52
EPHX1 P07099 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3940878 0.87 EPHX2 (1.00) EPHX2HRH3FAAHHPGDEPHX1
SCHEMBL3937867 0.85 EPHX2 (1.00) EPHX2HRH3HPGD
SCHEMBL14270955 0.83 EPHX2 (0.76) EPHX2HRH3
SCHEMBL3936504 0.82 EPHX2 (1.00) EPHX2FAAHHPGD
SCHEMBL3944877 0.81 EPHX2 (0.74) EPHX2HRH3P2RY1HPGD
SCHEMBL6538866 0.78 EPHX2 (0.67) EPHX2HRH3
SCHEMBL4383596 0.77 HRH3 (1.00) EPHX2HRH3
SCHEMBL1431303 0.76 EPHX2 (0.65) EPHX2HRH3HPGD
SCHEMBL19464796 0.76 EPHX2 (0.62) EPHX2HRH3HPGD
Hydrochloric Acid SCHEMBL4378203 0.76 HRH3 (1.00) EPHX2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101495119-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-07-29 CN claimed
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 EP claimed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO claimed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US claimed
CN-101495119-A Soluble epoxide hydrolase inhibitors ARETE THERAPEUTICS INC (US) 2009-07-29 CN disclosed
EP-2046329-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS Arete Therapeutics, INC. (US) 2009-04-15 EP disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed
WO-2008016884-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-02-07 WO disclosed
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032978-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 EPHX2 2/4885HRH3 160/4885P2RY1 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.